Previous Close | 0.0270 |
Open | 0.0250 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0250 - 0.0290 |
52 Week Range | 0.0200 - 0.0500 |
Volume | |
Avg. Volume | 153,666 |
Market Cap | 8.496M |
Beta (5Y Monthly) | 0.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0070 |
Earnings Date | Aug 28, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology. Featured Image for Gb Sciences Featured Image for Gb Sciences LAS VEGAS, July 19, 2022 (GLOBE NEWSWIRE) -- Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and analytics platform long before the pandemic sparked a digital transformation. According to
As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology. Featured Image for Gb Sciences Featured Image for Gb Sciences LAS VEGAS, July 18, 2022 (GLOBE NEWSWIRE) -- Gb Sciences is a plant-inspired, biopharmaceutical research and drug development company that began building its proprietary digital research and analytics platform long before the pandemic sparked a digital transformation. According to
Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that are more effective when used together than singularly, as demonstrated in an animal model of the disease. Featured Image for Gb Sciences Featured Image for Gb Sciences LAS VEGAS, May 23, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX),